The professor of neuroscience at the University of Cambridge discussed the biology of programmed axon death, the emergence of SARM1-targeted therapies, and the challenges of translating this pathway into treatments for neurologic conditions.
Michael Coleman, PhD
Advertisement
Articles by Michael Coleman, PhD
Advertisement
Latest Updated Articles
Goals for Expanding Knowledge on Programmed Axon DeathJune 16th 2026
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Insights on Vibrance-2 Study Results of Alixorexton in Narcolepsy Type 2: Richard K. Bogan, MD, FCCP, FAASM
2
FDA Clears Investigational New Drug Application for Remyelinating Agent PTD802 in Multiple Sclerosis
3
Pipeline Review: Alzheimer Disease Therapies by Mechanism of Action
4
FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis
5